CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
Nelson Labs Leuven Unveils Cutting-Edge Analytical Upgrade for Non-Volatile Extractables & Leachables Screening
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
World-Renowned Scientist and Co-founder of Moderna, Dr. Robert Langer, to Guide Sethera’s Scientific Strategy; Brigadier General Larry V. Lunt, USAF (Ret.), Adds Decades of Strategic Leadership Experience to Sethera’s Board
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
The partnership combines Tasso’s clinical grade blood collection solutions, such as the Tasso+ device pictured above, with ARUP’s gold standard testing capabilities to streamline and accelerate decentralized clinical research.
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
This new subscription service, exclusive to Owlet users, gives parents a deeper, personalized understanding of their baby’s development, health, and sleep trends.
Opening plenary session features latest fetal fraction amplification research
The Capitol Rotunda was filled with exhibits from over 25 local life sciences companies.
SALT LAKE CITY, January 23, 2025—Today BioUtah president and CEO Kelvyn Cullimore joined KSL Radio’s Inside Sources to discuss the life sciences industry in the State of Utah. Hosted by Maura Carabello and Adam Gardiner, Inside Sources daily broadcast covers political issues affecting Utah. Today, Carabello and Gardiner interviewed Cullimore to spotlight Utah’s life sciences industry and […]
Ultradent Donating to Southern California Fire Relief
Transaction positions iuvo BioScience for continued growth as an industry leader in ophthalmic clinical research
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs
SALT LAKE CITY, January 3, 2025—ARUP Laboratories today launched a new assay for the detection and subtyping of influenza A (H5) virus. This test will aid in the evaluation of individuals who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu. In early 2024, an outbreak […]
Sethera Therapeutics Completes First Funding Round
Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile
Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells
Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.
A new report from the U.’s Kem C. Gardner Policy Institute uncovers the wide-ranging mechanisms driving Utah’s high performance when it comes to innovation output
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics. The program, launching this month, will run for a minimum of three years.
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
Human Forms and Body Parts Trigger Strong Reactions in the Brain
